Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
N Engl J Med
    January 2018
  1. VAN DEN HEUVELEIBRINK MM, van der Kooi ALF, Wallace WHB
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:399-400.
    >> Share

  2. DONNEZ J, Dolmans MM
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:400-401.
    >> Share

    December 2017
  3. TURNER NC
    Signatures of DNA-Repair Deficiencies in Breast Cancer.
    N Engl J Med. 2017;377:2490-2492.
    >> Share

  4. MORCH LS, Skovlund CW, Hannaford PC, Iversen L, et al
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2017;377:2228-2239.
    >> Share

  5. DEMICHELE A, Yee D, Esserman L
    Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2017;377:2287-2289.
    >> Share

  6. HUNTER DJ
    Oral Contraceptives and the Small Increased Risk of Breast Cancer.
    N Engl J Med. 2017;377:2276-2277.
    >> Share

    November 2017
  7. PAN H, Gray R, Braybrooke J, Davies C, et al
    20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
    N Engl J Med. 2017;377:1836-1846.
    >> Share

  8. NAROD S, Booth CM, Foulkes WD
    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792.
    >> Share

  9. OIDE T, Mitsuishi T
    Pigmented Macule - A Skin Manifestation of Invasive Breast Cancer.
    N Engl J Med. 2017;377:1777.
    >> Share


  10. Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792-3.
    >> Share

  11. GREENE AK, Voss SD, Maclellan RA
    Liposuction for Swelling in Patients with Lymphedema.
    N Engl J Med. 2017;377:1788-1789.
    >> Share

    October 2017
  12. LEMERY S, Keegan P, Pazdur R
    First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
    N Engl J Med. 2017;377:1409-1412.
    >> Share

    September 2017
  13. RAMASWAMI R, Morrow M, Jagsi R
    Contralateral Prophylactic Mastectomy.
    N Engl J Med. 2017;377:1288-1291.
    >> Share

    August 2017
  14. RUADES NINFEA JI, Burdette-Radoux S, Wood ME
    Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:790-1.
    >> Share

  15. SPURDLE AB, Goldgar DE, Easton DF
    More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;377:795.
    >> Share


  16. More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;377:795-6.
    >> Share

  17. HIZAL M, Sendur MAN, Yalcin B
    Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:791.
    >> Share


  18. Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:791-2.
    >> Share


  19. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    N Engl J Med. 2017 Aug 9. doi: 10.1056/NEJMx170012.
    >> Share

    July 2017
  20. HAYMART MR, Miller DC, Hawley ST
    Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment?
    N Engl J Med. 2017;377:203-206.
    >> Share


  21. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2017 Jul 12. doi: 10.1056/NEJMx170011.
    >> Share

    June 2017
  22. SCHWARTZ RS, Erban JK
    Timing of Metastasis in Breast Cancer.
    N Engl J Med. 2017;376:2486-2488.
    >> Share

  23. LANNIN DR, Wang S
    Are Small Breast Cancers Good because They Are Small or Small because They Are Good?
    N Engl J Med. 2017;376:2286-91.
    >> Share

  24. VON MINCKWITZ G, Procter M, de Azambuja E, Zardavas D, et al
    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2017 Jun 5. doi: 10.1056/NEJMoa1703643.
    >> Share

  25. ROBSON M, Im SA, Senkus E, Xu B, et al
    Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    N Engl J Med. 2017 Jun 4. doi: 10.1056/NEJMoa1706450.
    >> Share

  26. MASUDA N, Lee SJ, Ohtani S, Im YH, et al
    Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    N Engl J Med. 2017;376:2147-2159.
    >> Share

    May 2017
  27. MOVASSAGH M, Mudvari P, Horvath A
    Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;376:2090-2091.
    >> Share

    January 2017
  28. PLICHTA JK, Hughes K
    Radiation-Induced Angiosarcoma after Breast-Cancer Treatment.
    N Engl J Med. 2017;376:367.
    >> Share

  29. DE GRAMONT A, Herrera A, de Gramont A
    Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:288.
    >> Share

  30. ARAKI K, Miyoshi Y
    Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:288.
    >> Share


  31. Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:289.
    >> Share

  32. BRENTNALL AR, Duffy SW, Cuzick J
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:94.
    >> Share


  33. Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93-95.
    >> Share

  34. KOPANS DB
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93-4.
    >> Share

  35. JATOI I, Anderson WF
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93.
    >> Share

    December 2016
  36. LYCETTE J
    Neglected - Cancer Care and Mental Health in Rural America.
    N Engl J Med. 2016;375:2220-2221.
    >> Share

  37. BLOK EJ, van de Velde CJ, Smit VT
    70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199.
    >> Share


  38. 70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199-2201.
    >> Share

  39. THEWES B, Prins J, Friedlander M
    70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199-2200.
    >> Share

    November 2016
  40. FINN RS, Martin M, Rugo HS, Jones S, et al
    Palbociclib and Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2016;375:1925-1936.
    >> Share

  41. SHERR CJ
    A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6.
    N Engl J Med. 2016;375:1920-1923.
    >> Share

  42. WOLFF AC
    CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard.
    N Engl J Med. 2016;375:1993-1994.
    >> Share

    October 2016
  43. BUYSE M, Saad ED, Burzykowski T
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1591-1594.
    >> Share


  44. Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1591-1594.
    >> Share

  45. SANZ A, Del Valle ML
    Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
    N Engl J Med. 2016;375:1590-1591.
    >> Share


  46. Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
    N Engl J Med. 2016;375:1590-1591.
    >> Share

  47. HARRINGTON D, Parmigiani G
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1593-4.
    >> Share

  48. JOENSUU H
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1592.
    >> Share

  49. WELCH HG, Prorok PC, O'Malley AJ, Kramer BS, et al
    Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.
    N Engl J Med. 2016;375:1438-1447.
    >> Share

  50. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2016.
    >> Share

    August 2016
  51. HUDIS CA, Dickler M
    Increasing Precision in Adjuvant Therapy for Breast Cancer.
    N Engl J Med. 2016;375:790-1.
    >> Share

  52. CARDOSO F, van't Veer LJ, Bogaerts J, Slaets L, et al
    70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:717-29.
    >> Share

  53. HUNTER DJ
    Uncertainty in the Era of Precision Medicine.
    N Engl J Med. 2016;375:711-3.
    >> Share

    July 2016
  54. POLLARD JW
    Defining Metastatic Cell Latency.
    N Engl J Med. 2016;375:280-2.
    >> Share

  55. GOSS PE, Ingle JN, Pritchard KI, Robert NJ, et al
    Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
    N Engl J Med. 2016;375:209-19.
    >> Share

  56. CAREY LA, Winer EP
    I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.
    N Engl J Med. 2016;375:83-4.
    >> Share

  57. RUGO HS, Olopade OI, DeMichele A, Yau C, et al
    Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    N Engl J Med. 2016;375:23-34.
    >> Share

  58. PARK JW, Liu MC, Yee D, Yau C, et al
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:11-22.
    >> Share

    June 2016
  59. MACINNIS RJ, Pike MC, Hopper JL
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2403-4.
    >> Share

  60. KARAM A
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2403.
    >> Share

  61. HARTMANN LC, Lindor NM
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2404.
    >> Share

  62. MENDELL JT
    Targeting a Long Noncoding RNA in Breast Cancer.
    N Engl J Med. 2016;374:2287-9.
    >> Share

  63. CHLEBOWSKI RT, Budoff MJ
    Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention.
    N Engl J Med. 2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016